GRPR and neoplasm: The heterodimer 177Lu-DOTA-RGD-BBN, targeting both αvβ3 and GRPR, showed good tumor uptake in PC-3 tumor models (5.88 ± 1.12% ID/g at 0.5 h), with decreasing retention over 48 h and favorable tumor-to-blood and T/M ratios.